Current treatment options for CLL

Prof. John Gribben, MD, DSc, FRCPath, FMed Sci from the Barts Cancer Institute, London, UK discusses the current treatment options for people with chronic lymphocytic leukemia (CLL) at the annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France. The treatment landscape for CLL has changed drastically with the introduction of new drugs such as ibrutinib, idelalisib, rituximab and venetoclax. These agents are reducing the number of stem cell transplants being performed however, it is important utilize the opportunity to plan and organise for it, especially patients with high-risk features. These new agents have many advantages such as low side effect profiles and good efficacy however, they are agents that patients need to take their entire life.